Device Trial Radar · NCT01306864
Hemostasis of Active Gastrointestinal (GI) Luminal Tract Bleeding
Last checked: Nov 19, 2026Latest source record: Feb 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
67
Actual
Start
Dec 2011
Primary completion
Apr 30, 2017
Study completion May 29, 2017
Sponsor
- Lead sponsor
- Cook Group IncorporatedNot on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 2, 2011
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to show that Hemospray is effective in achieving initial hemostasis and documenting rate of further bleed when compared to standard of care.
Conditions
- Bleeding Peptic Ulcers
Interventions
Hemospray KitDevice
Hemostasis of Arterial GI Bleeding
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients with further bleedTime frame: 72 Hours
Locations
12 sites in 4 countries. Site status is shown where the registry gives one.
Royal Alexandra
Edmonton, Alberta, Canada
Vancouver Coastal Health
Vancouver, British Columbia, Canada
Health Science Centre University of Manitoba
Winnipeg, Manitoba, Canada
9 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.